Corcept Therapeutics | CORT - Cash And Equivalent


Corcept Therapeutics reported $108.74M in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
Acadia Pharmaceuticals USD 851.46M 31.77M Mar/2026
Alaunos Therapeutics USD 354K 1.03M Mar/2026
ANI Pharmaceuticals USD 311.18M 25.59M Mar/2026
Ardelyx USD 31.21M 36.79M Mar/2026
Aurora Cannabis CAD 64.69M 8.33M Mar/2026
BioMarin Pharmaceutical USD 2.22B 910.76M Mar/2026
Bristol-Myers Squibb USD 9.57B 635M Mar/2026
Canopy Growth CAD 364.68M 6.64M Mar/2026
Corcept Therapeutics USD 108.74M 11.76M Mar/2026
Eli Lilly USD 5.28B 1.99B Mar/2026
J&J USD 21.69B 1.98B Mar/2026
Knight Therapeutics CAD 76.45M 5.43M Dec/2025
Lexicon Pharmaceuticals USD 38.09M 3.76M Mar/2026
Merck USD 5.33B 9.24B Mar/2026
Nektar Therapeutics USD 15.12M 25.92M Dec/2025
Novartis USD 6.88B 4.56B Mar/2026
Novartis USD 6.88B 2.68B Mar/2026
Omeros USD 1.9M 2.36M Jun/2025
Pacira USD 144.31M 14.24M Mar/2026
Pfizer USD 1.7B 561M Mar/2026
Supernus Pharmaceuticals USD 184.87M 56.42M Mar/2026
TG Therapeutics USD 442.21M 242.7M Mar/2026